Assertio Therapeutics Stock Analysis

Assertio Stock Analysis Notes

About 28.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.5. The entity recorded a loss per share of 4.5. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:15 split on the 26th of December 2025. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Assertio Therapeutics please contact Mark Reisenauer at 224 419 7106 or go to https://www.assertiotx.com.

Assertio Therapeutics Investment Alerts

Assertio Largest EPS Surprises

View All Earnings Estimates

Assertio Therapeutics Environmental, Social, and Governance (ESG) Scores

Assertio Stock Institutional Investors

Note, although Assertio Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Assertio Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.56 M.

Assertio Profitablity

The company has Profit Margin (PM) of (0.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.

Management Efficiency

Assertio Therapeutics has return on total asset (ROA) of (0.0417) % which means that it has lost $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2448) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2026. Return On Capital Employed is likely to drop to -0.14 in 2026. Liabilities And Stockholders Equity is likely to gain to about 335.7 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 74.2 M in 2026.

Technical Drivers

As of the 6th of February, Assertio Therapeutics shows the Downside Deviation of 3.27, mean deviation of 2.62, and Risk Adjusted Performance of 0.0336. Assertio Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Assertio Therapeutics Price Movement Analysis

Assertio Therapeutics Insider Trading Activities

Assertio Therapeutics Outstanding Bonds

Assertio Therapeutics Predictive Daily Indicators

Assertio Therapeutics Corporate Filings

Assertio Therapeutics Forecast Models

Assertio Therapeutics' time-series forecasting models are one of many Assertio Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Assertio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Assertio Therapeutics Bond Ratings

Assertio Therapeutics financial ratings play a critical role in determining how much Assertio Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Assertio Therapeutics' borrowing costs.

Assertio Therapeutics Debt to Cash Allocation

Assertio Therapeutics currently holds 40.27 M in liabilities with Debt to Equity (D/E) ratio of 0.49, which is about average as compared to similar companies. Assertio Therapeutics has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Assertio Therapeutics' use of debt, we should always consider it together with its cash and equity.

Assertio Therapeutics Total Assets Over Time

Assertio Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Assertio Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Assertio Therapeutics Debt Ratio

24.0

It appears most of the Assertio Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Assertio Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Assertio Therapeutics, which in turn will lower the firm's financial flexibility.

Assertio Therapeutics Corporate Bonds Issued

Assertio Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Assertio Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Assertio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Assertio Therapeutics. By using and applying Assertio Stock analysis, traders can create a robust methodology for identifying Assertio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Assertio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Assertio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Assertio Therapeutics stock analysis indicators help investors evaluate how Assertio Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Assertio Therapeutics shares will generate the highest return on investment. By understating and applying Assertio Therapeutics stock analysis, traders can identify Assertio Therapeutics position entry and exit signals to maximize returns.

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.